Welcome to our dedicated page for Quantum-Si Incorporated news (Ticker: QSI), a resource for investors and traders seeking the latest updates and insights on Quantum-Si Incorporated stock.
Quantum-Si Incorporated (Nasdaq: QSI) is a proteomics technology and life sciences company focused on single-molecule protein analysis and Next-Generation Protein Sequencing. This news page aggregates company-issued updates and market-moving announcements so readers can follow how Quantum-Si’s benchtop protein sequencing platform, chemistry kits, and data analysis tools are evolving over time.
Recent Quantum-Si news has highlighted product launches such as the V4 Sequencing Kit, which the company reports improves sequencing coverage through additional amino acid recognition, specialized enzymes, and enhanced algorithms. The company has also announced a Version 3 Library Preparation Kit designed for lower protein input and detection of low-abundance proteins, along with data analysis enhancements that unlock detection of additional amino acids and improve peptide alignment and protein inference.
Investors and researchers can use this page to track updates on Quantum-Si’s Proteus platform development, including prototype sequencing milestones, technology roadmap disclosures, and plans related to amino acid coverage, controlled cleavage chemistry, and post-translational modification methods. Financial news items, such as quarterly earnings releases, capital raising transactions, and lease or other material agreements disclosed via Form 8-K, also appear in this feed.
In addition, the news stream captures corporate governance and human capital updates, including inducement grants under the company’s 2023 Inducement Equity Incentive Plan, investor conference participation, and Investor & Analyst Day events. Bookmark this page to review Quantum-Si’s official press releases and regulatory news in one place, with a focus on developments that shape the company’s proteomics technology, commercialization efforts, and capital markets activity.
Quantum-Si Incorporated (NASDAQ: QSI), known as The Protein Sequencing Company™, will participate in the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA, from January 9-12, 2023. The company's management is set to present on January 12 at 10:30 am PST, discussing recent advancements including the launch of their innovative Platinum™ instrument, which enables next-generation single-molecule protein sequencing. A live and archived webcast will be available on the Quantum-Si website for those unable to attend.
Quantum-Si (NASDAQ: QSI) announced the launch of Platinum™, the first next-generation single-molecule protein sequencing platform, now available for $70,000. This innovative technology is expected to revolutionize the field of proteomics by providing broad access to high-resolution protein sequencing data, facilitating advancements in drug discovery and diagnostics. The company also appointed Grace Johnston, PhD, as Chief Commercial Officer to lead global sales and commercial activities. Shipments for the new platform are set to begin in Q1 2023.
Quantum-Si, known as The Protein Sequencing Company™, has joined the Human Proteome Organization (HUPO) Industrial Advisory Board. This collaboration aims to advance proteomics technologies and enhance understanding of human diseases. Dan Hanson and Dr. Brian Reed will represent Quantum-Si, which is actively participating in HUPO's 21st World Congress in Cancun and the upcoming US HUPO Conference in Chicago. CEO Jeff Hawkins emphasized the importance of protein sequencing in revolutionizing life science research and drug discovery.
Quantum-Si (Nasdaq: QSI) reported its third-quarter 2022 financial results, showing a net loss of $31.7 million, up from $18.1 million in Q3 2021. Operating expenses rose to $27.7 million, a 9.9% increase year-over-year, mainly driven by R&D costs reaching $16.7 million, compared to $11.1 million in the prior year. However, the company is lowering its operating expense growth guidance to 25-30% for 2022, down from 40-50%. Quantum-Si aims to launch its Platinum protein sequencing instrument by year-end 2022 and is managing costs effectively as it prepares for commercialization.
Quantum-Si (NASDAQ: QSI) announced its participation in the 16th Annual Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 17, 2022, in New York. CEO Jeff Hawkins and COO Patrick Schneider will engage in a fireside chat at 3:30 pm ET, discussing advancements in the commercialization of their innovative Platinum™ protein sequencing instrument, aimed at revolutionizing proteomics. A live and archived webcast will be available in the Investors section of the Quantum-Si website.
Quantum-Si Incorporated (NASDAQ: QSI) will announce its third-quarter 2022 financial results on November 7, 2022, after market close. Management will host a conference call at 4:30 p.m. ET on the same day to discuss these results and provide a business update. Quantum-Si focuses on advancing proteomics through its innovative semiconductor chip designed for single-molecule protein sequencing, enhancing drug discovery and diagnostics beyond traditional DNA sequencing methods.
Quantum-Si, a life sciences company (NASDAQ: QSI), announced a groundbreaking development in protein sequencing technology. Published in Science, their research presents a next-generation single-molecule protein sequencing platform utilizing semiconductor chips and Time Domain Sequencing™, offering real-time amino acid insights. This innovation promises to enhance drug discovery and diagnostics, significantly impacting biomedical research. Founded by Dr. Jonathan Rothberg, Quantum-Si aims to redefine proteomics, facilitating greater understanding of proteins and their roles in health and disease.
Quantum-Si Incorporated (NASDAQ: QSI) has appointed Jeff Hawkins as its new Chief Executive Officer, effective October 10, 2022. Hawkins succeeds Dr. Jonathan Rothberg, who has been Interim CEO since the company's founding. With over 20 years in life sciences, Hawkins previously led significant growth at Illumina and Truvian Sciences. He will oversee the launch of Quantum-Si's Platinum™ instrument, the first next-generation single-molecule protein sequencing platform. This transition aims to propel the company into a new growth phase.
Quantum-Si Incorporated (Nasdaq: QSI) announced participation in the Morgan Stanley 20th Annual Global Healthcare Conference from September 12-14, 2022, in New York, NY. Patrick Schneider, President and COO, will engage in a fireside chat on September 14, 2022, at 10:35 am ET. The discussion will focus on the company's advancements toward commercialization of the Platinum™ instrument, a pioneering platform for single-molecule protein sequencing. A live and archived webcast will be available in the Investors section of Quantum-Si's website.
Quantum-Si Incorporated (Nasdaq: QSI) reported its second quarter 2022 financial results, revealing a net loss of $32.4 million, an improvement from a loss of $35.7 million in Q2 2021. Operating expenses decreased 6% to $30.2 million. Research and development costs rose to $18.5 million due to increased product development activities. Despite the challenges, the company achieved significant milestones in protein sequencing, demonstrating recognition of 15 out of 20 amino acids. Quantum-Si maintains a strong cash position of $400.7 million, enabling continued business investments.
FAQ
What is the current stock price of Quantum-Si Incorporated (QSI)?
What is the market cap of Quantum-Si Incorporated (QSI)?
